Literature DB >> 3132386

Comparative in vitro activity of LY121019 and amphotericin B against clinical isolates of Candida species.

E D Spitzer1, S J Travis, G S Kobayashi.   

Abstract

LY121019 and amphotericin B were equally active in vitro against most clinical isolates of Candida albicans and Candida tropicalis. Higher concentrations of LY121019 were required for inhibition of Candida glabrata. Other Candida species were inhibited by amphotericin B but not by LY121019.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3132386     DOI： 10.1007/bf01962183

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


  6 in total

1.  Papulacandin B: an inhibitor of glucan synthesis in yeast spheroplasts.

Authors:  B C Baguley; G Römmele; J Gruner; W Wehrli
Journal:  Eur J Biochem       Date:  1979-07

Review 2.  Antifungal agents useful in therapy of systemic fungal infections.

Authors:  G Medoff; J Brajtburg; G S Kobayashi; J Bolard
Journal:  Annu Rev Pharmacol Toxicol       Date:  1983       Impact factor: 13.820

3.  Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy.

Authors:  R Horn; B Wong; T E Kiehn; D Armstrong
Journal:  Rev Infect Dis       Date:  1985 Sep-Oct

4.  Studies on the mechanism of antifungal action of aculeacin A.

Authors:  H Yamaguchi; T Hiratani; K Iwata; Y Yamamoto
Journal:  J Antibiot (Tokyo)       Date:  1982-02       Impact factor: 2.649

5.  In vitro and in vivo anti-Candida activity and toxicology of LY121019.

Authors:  R S Gordee; D J Zeckner; L F Ellis; A L Thakkar; L C Howard
Journal:  J Antibiot (Tokyo)       Date:  1984-09       Impact factor: 2.649

6.  Incidence of polyene-resistant yeasts recovered from clinical specimens.

Authors:  J D Dick; W G Merz; R Saral
Journal:  Antimicrob Agents Chemother       Date:  1980-07       Impact factor: 5.191
  6 in total
  17 in total

1.  In vitro studies of activities of some antifungal agents against Candida albicans ATCC 10231 by the turbidimetric method.

Authors:  M T Blanco; C Pérez-Giraldo; J Blanco; F J Morán; C Hurtado; A C Gómez-García
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

2.  In vitro and in vivo activities of Sch 39304, fluconazole, and amphotericin B against Histoplasma capsulatum.

Authors:  G S Kobayashi; S J Travis; M G Rinaldi; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

Review 3.  Antifungal peptides: novel therapeutic compounds against emerging pathogens.

Authors:  A J De Lucca; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

4.  Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors.

Authors:  D M Schmatz; M A Romancheck; L A Pittarelli; R E Schwartz; R A Fromtling; K H Nollstadt; F L Vanmiddlesworth; K E Wilson; M J Turner
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

5.  Comparative effects of cilofungin and amphotericin B on experimental murine candidiasis.

Authors:  C J Morrison; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

Review 6.  In vitro and in vivo evaluation of antifungal agents.

Authors:  A Espinel-Ingroff; S Shadomy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-04       Impact factor: 3.267

7.  In vitro activity of the new semi-synthetic polypeptide cilofungin (LY121019) against Aspergillus and Candida species.

Authors:  A Huang; F Edwards; E M Bernard; D Armstrong; H J Schmitt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-09       Impact factor: 3.267

8.  Comparative efficacies of cilofungin (Ly121019) and amphotericin B against disseminated Candida albicans infection in normal and granulocytopenic mice.

Authors:  N Khardori; H Nguyen; L C Stephens; L Kalvakuntla; B Rosenbaum; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

9.  Synergy between cilofungin and amphotericin B in a murine model of candidiasis.

Authors:  L H Hanson; A M Perlman; K V Clemons; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

10.  Antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3-beta-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental disseminated candidiasis.

Authors:  T J Walsh; J W Lee; P Kelly; J Bacher; J Lecciones; V Thomas; C Lyman; D Coleman; R Gordee; P A Pizzo
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.